Summary
Genomics and all the associated technologies it has spawned have fundamentally changed the way research and development organizations carry out the work they do in the early stages of discovery. However, successful organizations must move from product concept through to registration as efficiently as possible. In order to achieve this, the early “basic” science must be combined with the clinical perspective from the start. Furthermore, since the genomics industry was first established in the early 1990s it has evolved from tool and data suppliers to drug development companies. It is therefore likely that we will see technology advances in genomics become more limited in the years ahead.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Abbreviations
- cDNA:
-
copy deoxyribonucleic acid
- Cox2:
-
cyclooxygenase 2
- DMOAD:
-
disease-modifying osteoarthritis drug
- iNOS:
-
nitric oxide synthase
- mRNA:
-
messenger ribonucleic acid
- NCBI:
-
National Center for Biotechnology Information
- OA:
-
osteoarthritis
- SNP:
-
single nucleotide polymorphism
References
P. Spence, in: E. Jucker (ed.): Progress in Drug Research 53, Birkhäuser Verlag, Basel 1999, 157–191.
A. Abuin, K.H. Holt, K.A. Platt, A.T. Sands and B.P. Zambrowicz:1111 Trends Biotechnol. 20 36 (2002).
J. Rees: Science 296 698 (2002).
M. Schena, R.A. Heller, T.P. Theriault, K. Konrad, E. Lachenmeier and R.W. Davis: Trends Biotechnol. 16 301 (1998).
J.H. Wang and R.M. Hewick: Drug Discov. Today 4, 129 (1999).
M.J. Valler and D. Green: Drug Discov. Today 5, 286 (2000).
S. Dry, S. McCarthy and T. Harris: Nat. Struct. Biol., Structural Genomics Supplement 7 (11), 946 (2000).
R.B. Russell and D.S. Eggleston: Nat. Struct. Biol., Structural Genomics Supplement 7 (11), 928 (2000).
D. Xu, Y. Xu and E.C. Uberbacher: Curr. Prot. Pept. Sci. 1, 1 (2000).
S.K. Burnley and J.B. Bonanno: Ann. Rev. Genom. Hum. Genet. 3, 243 (2002).
L.G. Cote: J. Am. Acad. Nurse Pract. 13 495 (2001).
J.J. Deeks, L.A. Smith and M.D. Bradley: Br. Med. J. 325 619 (2002).
H.J. Hauselmann: Best Pract. Res. Clin. Rheumatol. 15 595 (2001).
T. Cawston: Mol. Med. Today 4, 130 (1998).
L. Peltonen and V.A. McKusick: Science 291 1224 (2001).
T. Gura: Science 297 1982 (2002).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Basel AG
About this chapter
Cite this chapter
Spence, P. (2003). Maximizing the value of genomics in the drug discovery and development process. In: Jucker, E. (eds) Progress in Drug Research. Progress in Drug Research, vol 60. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8012-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8012-1_5
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9402-9
Online ISBN: 978-3-0348-8012-1
eBook Packages: Springer Book Archive